Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme-Reference-Cited by-同舟云学术

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme

Published:2016-12 Issue:12 Volume:3 Page:1115-1128
ISSN:2215-0366
Container-title:The Lancet Psychiatry
language:en
Short-container-title:The Lancet Psychiatry

Author:

Bugarski-Kirola Dragana,Iwata Nakao,Sameljak Snjezana,Reid Carol,Blaettler Thomas,Millar Laurie,Marques Tiago Reis,Garibaldi George,Kapur Shitij

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference50 articles.

1. Schizophrenia;van Os;Lancet,2009

2. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia;Lieberman;N Engl J Med,2005

3. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs;Miyamoto;Mol Psychiatry,2005

4. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world;Mortimer;Clin Schizophr Relat Psychoses,2010

5. The heterogeneity of schizophrenia in disease states;Mohr;Schizophr Res,2004

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erythropoietic protoporphyrias: updates and advances;Trends in Molecular Medicine;2024-09

2. A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis;Cell Metabolism;2024-08

3. Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia;Biochemical Pharmacology;2024-06

4. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments;Pharmacopsychiatry;2024-05-06

5. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia;Biochemical Pharmacology;2024-05